Stockscreener 앱 받기
13.76
0.44%
0.06
시간 외 거래:
13.85
0.09
+0.65%
전일 마감가:
$13.70
열려 있는:
$13.61
하루 거래량:
4.08M
Relative Volume:
1.48
시가총액:
$1.19B
수익:
$139.71M
순이익/손실:
$-209.36M
주가수익비율:
-4.6486
EPS:
-2.96
순현금흐름:
$-160.60M
1주 성능:
+4.96%
1개월 성능:
-11.79%
6개월 성능:
+0.22%
1년 성능:
-27.50%
1일 변동 폭
$13.36
$14.36
1주일 범위
$13.02
$14.36
52주 변동 폭
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
SNDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.76 | 1.18B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks
Syndax Pharmaceuticals (SNDX) Q3 2025 Earnings: Revenue Jumps 21% - GuruFocus
Syndax Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Transcript : Syndax Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Syndax Pharmaceuticals Q3 Earnings: EPS of -$0.70 Beats Estimate, Revenue of $45.9M Misses Estimate - GuruFocus
Syndax: Q3 Earnings Snapshot - News-Times
Syndax Pharmaceuticals Grows Revenue As Wall Street Stays Bullish - Finimize
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Syndax Pharmaceuticals falls as Q3 revenue misses estimates - Investing.com
SNDX: Syndax Pharmaceuticals to Showcase Promising Data at ASH 2 - GuruFocus
Is Syndax Pharmaceuticals Inc. stock poised for growth2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 - The Manila Times
Syndax Announces Compelling Revuforj® (revumenib) and - GlobeNewswire
Syndax (NASDAQ: SNDX) to present Revuforj and Niktimvo data in 23 ASH 2025 abstracts - Stock Titan
How Syndax Pharmaceuticals Inc. stock performs in rate cut cycles2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Using Ichimoku Cloud for Syndax Pharmaceuticals Inc. technicals2025 Big Picture & Entry and Exit Point Strategies - newser.com
Leading vs lagging indicators on Syndax Pharmaceuticals Inc. performanceJuly 2025 Short Interest & Entry Point Confirmation Alerts - newser.com
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metricsMarket Activity Recap & Weekly Momentum Picks - newser.com
AlphaQuest LLC Sells 18,370 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Applying Wyckoff theory to Syndax Pharmaceuticals Inc. stockBreakout Watch & Verified Technical Trade Signals - newser.com
Detecting support and resistance levels for Syndax Pharmaceuticals Inc.Jobs Report & Verified Swing Trading Watchlist - newser.com
Is it too late to sell Syndax Pharmaceuticals Inc.Weekly Trade Summary & Growth-Oriented Investment Plans - newser.com
Will Syndax Pharmaceuticals Inc. stock maintain momentum in 2025Portfolio Value Report & Accurate Trade Setup Notifications - newser.com
Is Syndax Pharmaceuticals Inc. stock reversal real or fakeMarket Trend Report & Community Verified Watchlist Alerts - newser.com
How Syndax Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Chart Watch & Verified Momentum Watchlists - newser.com
Is Syndax Pharmaceuticals Inc. showing signs of accumulationMarket Volume Summary & AI Driven Stock Movement Reports - newser.com
Syndax Pharmaceuticals (SNDX) Q3 Earnings Preview: Key Expectati - GuruFocus
Kura Oncology's Ziftomenib Poised For Differentiation (NASDAQ:KURA) - Seeking Alpha
How risky is Syndax Pharmaceuticals Inc. stock nowJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Y Intercept Hong Kong Ltd Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
B. Riley Issues Optimistic Estimate for SNDX Earnings - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Previe - GuruFocus
Syndax Pharmaceuticals Hits Day Low at $13.03 Amid Price Pressure - Markets Mojo
Syndax Pharmaceuticals’ Promising AML Study Update: Key Insights for Investors - TipRanks
Is Syndax Pharmaceuticals Inc. (1T3) stock considered safe havenJuly 2025 Sentiment & Fast Moving Stock Watchlists - newser.com
Why Syndax Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Selloffs & Weekly Momentum Picks - newser.com
Published on: 2025-10-30 09:56:20 - newser.com
Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib - MSN
Syndax Announces Participation in November Investor Conferences - The Manila Times
Is Syndax Pharmaceuticals Inc. (1T3) stock a buy during volatile marketsEarnings Risk Summary & Smart Investment Allocation Insights - newser.com
Syndax (Nasdaq: SNDX) to join fireside chats at UBS, Guggenheim, Stifel, Jefferies - Stock Titan
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):